Biomarin Pharmaceutical Stock Options
| BMRN Stock | USD 71.53 0.46 0.64% |
Biomarin Pharmaceutical's latest option contracts expiring on May 16th 2025 are carrying combined implied volatility of 0.44. The Biomarin Pharmaceutical option chain provides detailed quote and price information for the current Biomarin Pharmaceutical option contracts. It shows all of Biomarin Pharmaceutical's listed puts, calls, expiration dates, strike prices, and other pricing information.
Biomarin Pharmaceutical Maximum Pain Price Across 2025-05-16 Option Contracts
Max pain occurs when Biomarin Pharmaceutical's market makers reach a net positive position across all Biomarin Pharmaceutical's options at a strike price where option holders stand to lose the most money. By contrast, Biomarin Pharmaceutical's option sellers may reap the most after selling more options than buying, causing them to expire worthless.
In The Money vs. Out of Money Option Contracts on Biomarin Pharmaceutical
Analyzing Biomarin Pharmaceutical's in-the-money options over time can help investors to take a profitable long position in Biomarin Pharmaceutical regardless of its overall volatility. This is especially true when Biomarin Pharmaceutical's options are deep in the money. These options can be identified using deltas that are over 0.75. Deep in-the-money Biomarin Pharmaceutical's options could be used as guardians of the underlying stock as they move almost dollar for dollar with Biomarin Pharmaceutical's stock while costing only a fraction of its price.
Please note that buying 'in-the-money' options on Biomarin Pharmaceutical lessens the impact of time decay, as they carry both intrinsic and time value. So, even if Biomarin Pharmaceutical's value remains static through the expiration date, the investor can sell to close an 'in-the-money' option to avoid a potential loss. However, in-the-money Biomarin Pharmaceutical contracts are usually more expensive to enter than their out-of-the-money counterparts. So keep in mind that while the payoffs on an in-the-money trade can be high, the investors could ultimately experience a more consequential loss if Biomarin Stock moves the wrong way.
Biomarin Pharmaceutical In The Money Call Balance
When Biomarin Pharmaceutical's strike price is surpassing the current stock price, the option contract against Biomarin Pharmaceutical stock is said to be in the money. When it comes to buying Biomarin Pharmaceutical's options that are 'In the Money' or 'Out of the Money', the choice depends on your outlook for the underlying security, financial situation, and what you are trying to achieve.
While 'out-of-the-money' option contracts written on Biomarin Pharmaceutical are typically viewed as the more aggressive, there are potential upsides to purchasing these types of options contracts. For one, the cost to buy an 'Out of the Money' option is lower than the cost to buy an 'In the Money' option. This cost-benefit is due to the fact that at the time of the purchase, 'Out of the Money' contracts have no intrinsic value. So, while the potential for a 100% loss is more significant, the cost and risk to enter the trade are lower.
Biomarin Current Options Market Mood
Biomarin Pharmaceutical's open interest and total value indicators provide investors with the necessary information to digest the overall options buildup for its expiring contracts. In addition, it helps Biomarin Stock's traders understand whether a recent fall or rise in the market is unreasonable and if the time has come to take contrarian positions. These ratios are calculated based on options trading volumes and current open interest.
Put-to-Call Volume
Unfortunately, most Biomarin Pharmaceutical's options investors are not very successful. Biomarin Pharmaceutical's option open interest and volume spread between outstanding puts and calls are regarded by many investors as reliable indicators of the overall future market direction.
Rule 16 of the current Biomarin contract
Base on the Rule 16, the options market is currently suggesting that Biomarin Pharmaceutical will have an average daily up or down price movement of about 0.0275% per day over the life of the 2025-05-16 option contract. With Biomarin Pharmaceutical trading at USD 71.53, that is roughly USD 0.0197. If you think that the market is fully incorporating Biomarin Pharmaceutical's daily price movement you should consider buying Biomarin Pharmaceutical options at the current volatility level of 0.44%. But if you have an opposite viewpoint you should avoid it and even consider selling them.
Biomarin |
Purchasing Biomarin Pharmaceutical options can give investors a meaningful hedge against losses and, therefore, could be used conservatively to decrease the volatility of your portfolio. However, many options could also amount to little more than gambling, significantly enhancing your overall portfolio risk. One simple example of these aggressive strategies is the sale of "uncovered" Biomarin calls. Remember, the seller must deliver Biomarin Pharmaceutical stock to the call owner when a call is exercised.
Biomarin Pharmaceutical Option Chain
When Biomarin Pharmaceutical's strike price is surpassing the current stock price, the option contract against Biomarin Pharmaceutical stock is said to be in the money. When it comes to buying options that are ITM or OTM, the choice depends on your outlook for the underlying security, financial situation, and what you are trying to achieve.
Biomarin Pharmaceutical's option chain is a display of a range of information that helps investors for ways to trade options on Biomarin. In general, an option chain provides a helpful tool for investors to see all available option contracts, both puts, and calls, for Biomarin. It also shows strike prices and maturity days for a Biomarin Pharmaceutical against a given expiration period. The table below combines all the option information in the form of a chain but before you use it, remember that it entails significant risk and it is not for everyone. | Open Int | Strike Price | Current Spread | Last Price | |||
Call | BMRN250516C00105000 | 0 | 105.0 | 0.0 - 1.1 | 1.1 | |
Call | BMRN250516C00100000 | 0 | 100.0 | 0.0 - 1.05 | 1.05 | |
Call | BMRN250516C00095000 | 0 | 95.0 | 0.0 - 1.05 | 1.05 | |
Call | BMRN250516C00090000 | 0 | 90.0 | 0.0 - 2.15 | 2.15 | |
Call | BMRN250516C00085000 | 0 | 85.0 | 0.0 - 1.3 | 1.3 | |
Call | BMRN250516C00080000 | 0 | 80.0 | 0.6 - 1.3 | 0.6 | |
Call | BMRN250516C00077500 | 0 | 77.5 | 1.15 - 1.6 | 1.45 | |
Call | BMRN250516C00075000 | 0 | 75.0 | 1.75 - 2.55 | 1.75 | |
Call | BMRN250516C00072500 | 0 | 72.5 | 2.7 - 3.4 | 3.26 | |
Call | BMRN250516C00070000 | 0 | 70.0 | 4.2 - 4.5 | 4.2 | In |
Put | BMRN250516P00105000 | 0 | 105.0 | 32.1 - 35.2 | 32.1 | In |
Put | BMRN250516P00100000 | 0 | 100.0 | 27.2 - 30.8 | 27.2 | In |
Put | BMRN250516P00095000 | 0 | 95.0 | 22.1 - 25.9 | 22.1 | In |
Put | BMRN250516P00090000 | 0 | 90.0 | 17.1 - 20.9 | 17.1 | In |
Put | BMRN250516P00085000 | 0 | 85.0 | 12.1 - 15.3 | 12.1 | In |
Put | BMRN250516P00080000 | 14 | 80.0 | 9.0 - 9.6 | 8.69 | In |
Put | BMRN250516P00077500 | 0 | 77.5 | 6.9 - 7.7 | 6.9 | In |
Put | BMRN250516P00075000 | 0 | 75.0 | 5.2 - 5.9 | 5.2 | In |
Put | BMRN250516P00072500 | 0 | 72.5 | 3.5 - 4.4 | 3.5 | In |
Put | BMRN250516P00070000 | 0 | 70.0 | 2.2 - 3.6 | 2.2 |
Biomarin Pharmaceutical Market Cap Over Time
Market Cap |
| Timeline |
Biomarin Total Stockholder Equity
Total Stockholder Equity |
|
Biomarin Pharmaceutical Corporate Management
| Laura Woodhead | VP Counsel | Profile | |
| George Davis | Chief VP | Profile | |
| Traci McCarty | Group Relations | Profile | |
| Jonathan Day | Executive Science | Profile | |
| Cristin Hubbard | Executive Officer | Profile | |
| Marni Kottle | Executive Officer | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biomarin Pharmaceutical. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Biomarin Stock, please use our How to Invest in Biomarin Pharmaceutical guide.You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biomarin Pharmaceutical. If investors know Biomarin will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biomarin Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 6.449 | Earnings Share 2.21 | Revenue Per Share | Quarterly Revenue Growth 0.156 | Return On Assets |
The market value of Biomarin Pharmaceutical is measured differently than its book value, which is the value of Biomarin that is recorded on the company's balance sheet. Investors also form their own opinion of Biomarin Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Biomarin Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biomarin Pharmaceutical's market value can be influenced by many factors that don't directly affect Biomarin Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biomarin Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biomarin Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biomarin Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.